Reference
·Supporting source
Thailand Precision Medicine Test-Type Mix — 2026 Estimate
CDx 48% / PGx 22% / liquid biopsy 18% / PRS 12%
Insight Research estimates the 2026 Thai precision-medicine spend mix at approximately 48% oncology companion diagnostics (HER2, EGFR, BRCA, KRAS, ALK, PD-L1), 22% pharmacogenomics (CYP2C9, CYP2C19, HLA-B*1502, DPYD), 18% liquid biopsy and ctDNA monitoring, and 12% polygenic risk scores plus hereditary cancer panels. CDx dominates because NHSO bundle inclusion plus pharma-paired access programmes drive the scaling wedge. PGx is anchored by mandatory HLA-B*1502 screening before carbamazepine and expanding CYP-family screening into cardiology and psychiatry. Liquid biopsy retains the highest unit margin (60-75% gross) but NHSO bundle inclusion is targeted for late 2027.
Figure in context
Insight Research estimates the 2026 Thai precision-medicine spend mix at approximately 48% oncology companion diagnostics (HER2, EGFR, BRCA, KRAS, ALK, PD-L1), 22% pharmacogenomics (CYP2C9, CYP2C19, HLA-B*1502, DPYD), 18% liquid biopsy and ctDNA monitoring, and 12% polygenic risk scores plus hereditary cancer panels. CDx dominates because NHSO bundle inclusion plus pharma-paired access programmes drive the scaling wedge. PGx is anchored by mandatory HLA-B*1502 screening before carbamazepine and expanding CYP-family screening into cardiology and psychiatry. Liquid biopsy retains the highest unit margin (60-75% gross) but NHSO bundle inclusion is targeted for late 2027.
Insight Research estimates the 2026 Thai precision-medicine spend mix at approximately 48% oncology companion diagnostics (HER2, EGFR, BRCA, KRAS, ALK, PD-L1), 22% pharmacogenomics (CYP2C9, CYP2C19, HLA-B*1502, DPYD), 18% liquid biopsy and ctDNA monitoring, and 12% polygenic risk scores plus hereditary cancer panels. CDx dominates because NHSO bundle inclusion plus pharma-paired access programmes drive the scaling wedge. PGx is anchored by mandatory HLA-B*1502 screening before carbamazepine and expanding CYP-family screening into cardiology and psychiatry. Liquid biopsy retains the highest unit margin (60-75% gross) but NHSO bundle inclusion is targeted for late 2027.
Time scope
FY2026
Source basis
Supporting source
Interpretation notes
What this tells you
Insight Research estimates the 2026 Thai precision-medicine spend mix at approximately 48% oncology companion diagnostics (HER2, EGFR, BRCA, KRAS, ALK, PD-L1), 22% pharmacogenomics (CYP2C9, CYP2C19, HLA-B*1502, DPYD), 18% liquid biopsy and ctDNA monitoring, and 12% polygenic risk scores plus hereditary cancer panels. CDx dominates because NHSO bundle inclusion plus pharma-paired access programmes drive the scaling wedge. PGx is anchored by mandatory HLA-B*1502 screening before carbamazepine and expanding CYP-family screening into cardiology and psychiatry. Liquid biopsy retains the highest unit margin (60-75% gross) but NHSO bundle inclusion is targeted for late 2027.
What not to do with it
Use the linked report for interpretation and keep basis differences explicit.
Related figures
Adjacent numbers that add context without drowning the value.
Thailand Precision Medicine Market Size — 2027 Projection
NHSO NLEM planning documents, Thai FDA NGS CDx framework draft, lab operator filings, hospital programme disclosures, Insight Research triangulation
Genome Thailand Cohort Size — 2026 Milestone
DMSc Genome Thailand programme documents, NIH-DMSc, MoPH
NHSO Priority CDx Panels Added to Oncology Bundles — FY2026-2027
NHSO National List of Essential Medicines planning documents, NHSO public consultations, hospital partner disclosures
Thailand Hospital-Integrated Personalised Cancer Package ASP
BDMS, Bumrungrad, BNH, Vejthani programme disclosures, Insight Research triangulation
Thailand Precision Medicine Operator Concentration — Top 6 Share
Operator disclosures, hospital programme websites, lab filings, Insight Research triangulation
Thailand Clinical NGS Oncology Panel Cost-of-Goods (50-gene panel)
Lab operator filings, Asia Genomics, Quantum Tech), reagent supplier benchmarks, Insight Research triangulation
Report context
Atlas actors in this figure's reports
Profiles covered in the report that cite this number.